A Multicenter, Double-Blind, Flexible-Dose, 6-Month Trial Comparing the Efficacy and Safety of Asenapine With Olanzapine in Stable Subjects With Predominant, Persistent Negative Symptoms of Schizophrenia.
Latest Information Update: 19 Aug 2024
At a glance
- Drugs Asenapine (Primary) ; Olanzapine
- Indications Schizophrenia
- Focus Therapeutic Use
- Acronyms APHRODITE
- Sponsors Merck Sharp & Dohme; Organon
- 13 Jun 2019 Trial has been completed in UK and Spain.
- 22 Dec 2011 Primary endpoint 'Positive-and-Negative-Syndrome-Scale' has not been met.
- 17 Jan 2008 Status changed from recruiting to completed.